Financings in Brief: Avitar
This article was originally published in The Gray Sheet
Avitar: Registration statement filed with the Securities and Exchange Commission for the offering of 13 mil. shares (including 12.7 mil. by the company and 361,000 by selling shareholders) has been declared effective, the firm states. The shares offered by the company would be issued if "redeemable warrants and certain other warrants were exercised." If all warrants were exercised, the aggregate exercise price would be about $21.6 mil. the firm states. "Proceeds, if any, will be used to continue to expand the business" and for "general working capital purposes," Avitar says...
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.